| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;100:1816-1822.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Regression of Atherosclerosis Induced by Liver-Directed Gene Transfer of Apolipoprotein A-I in Mice
From the Department of Medicine, University of Pennsylvania School of Medicine (R.K.T., K.T., D.J.R.), and the Wistar Institute (S.H.C., E.P.), Philadelphia, Pa, and the University of Delaware, Newark (D.U.).
Correspondence to Daniel J. Rader, MD, University of Pennsylvania Medical Center, 409 Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA 19104. E-mail rader{at}mail.med.upenn.edu
Background—The ability of apolipoprotein (apo)A-I to induce regression of preexisting atherosclerotic lesions has not been determined, and a mouse model of atherosclerosis regression has not yet been reported.
Methods and Results—LDL receptor–deficient mice were fed a western-type diet for 5 weeks to induce atherosclerotic lesions. A second-generation recombinant adenovirus encoding human apoA-I or a control adenovirus were injected intravenously in order to express apoA-I in the liver. Three days after injection, total apoA-I levels in mice injected with the apoA-I–expressing adenovirus were 216±16.0 mg/dL, compared with 68.0±3.0 mg/dL in control virus–injected mice (P<0.001). HDL cholesterol levels in mice injected with the AdhapoA-I vector 7 days after injection were 189±21.0 mg/dL, compared with 123±8.0 mg/dL in control virus-injected mice (P<0.02). Total and non-HDL cholesterol levels did not differ between the 2 groups. Atherosclerotic lesion area was quantified by en face analysis of the aorta and cross-sectional analysis of the aortic root. Compared with baseline mice, atherosclerosis progressed in mice injected with the control adenovirus. In contrast, in mice expressing apoA-I compared with baseline mice, total en face aortic lesion area was reduced by 70% and aortic root lesion was reduced by 46%. Expression of apoA-I was associated with a significant reduction in the fraction of lesions occupied by macrophages and macrophage-derived foam cells.
Conclusions—Liver-directed gene transfer of human apoA-I resulted in significant regression of preexisting atherosclerotic lesions in LDL receptor–deficient mice as assessed by 2 independent methods.
Key Words: atherosclerosis • liver • genes • apolipoproteins
This article has been cited by other articles:
 |
|
 |
|
  H. Nakaya, B. D. Summers, A. C. Nicholson, A. M. Gotto Jr., D. P. Hajjar, and J. Han Atherosclerosis in LDLR-Knockout Mice Is Inhibited, but Not Reversed, by the PPAR{gamma} Ligand Pioglitazone Am. J. Pathol., June 1, 2009; 174(6): 2007 - 2014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-A. Rye, C. A. Bursill, G. Lambert, F. Tabet, and P. J. Barter The metabolism and anti-atherogenic properties of HDL J. Lipid Res., April 1, 2009; 50(Supplement): S195 - S200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L.E. MacDonald, M. van Eck, R. B. Hildebrand, B. W.C. Wong, N. Bissada, P. Ruddle, A. Kontush, H. Hussein, M. A. Pouladi, M. J. Chapman, et al. Despite Antiatherogenic Metabolic Characteristics, SCD1-Deficient Mice Have Increased Inflammation and Atherosclerosis Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 341 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Millar, D. Duffy, R. Gadi, L. T. Bloedon, R. L. Dunbar, M. L. Wolfe, R. Movva, A. Shah, I. V. Fuki, M. McCoy, et al. Potent and Selective PPAR-{alpha} Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 140 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. K. Mishra, M. N. Palgunachari, N. R. Krishna, J. Glushka, J. P. Segrest, and G. M. Anantharamaiah Effect of Leucine to Phenylalanine Substitution on the Nonpolar Face of a Class A Amphipathic Helical Peptide on Its Interaction with Lipid: HIGH RESOLUTION SOLUTION NMR STUDIES OF 4F-DIMYRISTOYLPHOSPHATIDYLCHOLINE DISCOIDAL COMPLEX J. Biol. Chem., December 5, 2008; 283(49): 34393 - 34402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Moerland, H. Samyn, T. van Gent, R. van Haperen, G. Dallinga-Thie, F. Grosveld, A. van Tol, and R. de Crom Acute Elevation of Plasma PLTP Activity Strongly Increases Pre-existing Atherosclerosis Arterioscler Thromb Vasc Biol, July 1, 2008; 28(7): 1277 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Davidson, P. M. Meyer, S. Haffner, S. Feinstein, R. D'Agostino Sr, G. T. Kondos, A. Perez, Z. Chen, and T. Mazzone Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus Circulation, April 22, 2008; 117(16): 2123 - 2130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Hsueh, E. D. Abel, J. L. Breslow, N. Maeda, R. C. Davis, E. A. Fisher, H. Dansky, D. A. McClain, R. McIndoe, M. K. Wassef, et al. Recipes for Creating Animal Models of Diabetic Cardiovascular Disease Circ. Res., May 25, 2007; 100(10): 1415 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wang, B. G. Sharifi, T. Pan, L. Song, A. Yukht, and P. K. Shah Bone Marrow Transplantation Shows Superior Atheroprotective Effects of Gene Therapy With Apolipoprotein A-I Milano Compared With Wild-Type Apolipoprotein A-I in Hyperlipidemic Mice J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1459 - 1468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kitajima, D. H.L. Marchadier, G. C. Miller, G.-p. Gao, J. M. Wilson, and D. J. Rader Complete Prevention of Atherosclerosis in ApoE-Deficient Mice by Hepatic Human ApoE Gene Transfer With Adeno-Associated Virus Serotypes 7 and 8 Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1852 - 1857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. MacDougall, F. Kramer, P. Polinsky, S. Barnhart, B. Askari, F. Johansson, R. Varon, M. E. Rosenfeld, K. Oka, L. Chan, et al. Aggressive Very Low-Density Lipoprotein (VLDL) and LDL Lowering by Gene Transfer of the VLDL Receptor Combined with a Low-Fat Diet Regimen Induces Regression and Reduces Macrophage Content in Advanced Atherosclerotic Lesions in LDL Receptor-Deficient Mice Am. J. Pathol., June 1, 2006; 168(6): 2064 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cuchel and D. J. Rader Macrophage Reverse Cholesterol Transport: Key to the Regression of Atherosclerosis? Circulation, May 30, 2006; 113(21): 2548 - 2555. [Full Text] [PDF]
|
|
|
|
|
|
V. K. Mishra, G. M. Anantharamaiah, J. P. Segrest, M. N. Palgunachari, M. Chaddha, S. W. S. Sham, and N. R. Krishna Association of a Model Class A (Apolipoprotein) Amphipathic {alpha} Helical Peptide with Lipid: HIGH RESOLUTION NMR STUDIES OF PEPTIDE{middle dot}LIPID DISCOIDAL COMPLEXES J. Biol. Chem., March 10, 2006; 281(10): 6511 - 6519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Duffy and D. J. Rader Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport Circulation, February 28, 2006; 113(8): 1140 - 1150. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ohashi, H. Mu, X. Wang, Q. Yao, and C. Chen Reverse cholesterol transport and cholesterol efflux in atherosclerosis QJM, December 1, 2005; 98(12): 845 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Oram and J. W. Heinecke ATP-Binding Cassette Transporter A1: A Cell Cholesterol Exporter That Protects Against Cardiovascular Disease Physiol Rev, October 1, 2005; 85(4): 1343 - 1372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Gruen, M. R. Plummer, W. Zhang, K. A. Posey, M. Linton, S. Fazio, and A. H. Hasty Persistence of high density lipoprotein particles in obese mice lacking apolipoprotein A-I J. Lipid Res., September 1, 2005; 46(9): 2007 - 2014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Johnsen, E. B. Mathiesen, E. Fosse, O. Joakimsen, E. Stensland-Bugge, I. Njolstad, and E. Arnesen Elevated High-Density Lipoprotein Cholesterol Levels Are Protective Against Plaque Progression: A Follow-Up Study of 1952 Persons With Carotid Atherosclerosis The Tromso Study Circulation, July 26, 2005; 112(4): 498 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Levin, E. D. Bischoff, C. L. Daige, D. Thomas, C. T. Vu, R. A. Heyman, R. K. Tangirala, and I. G. Schulman Macrophage Liver X Receptor Is Required for Antiatherogenic Activity of LXR Agonists Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 135 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Li, K.-Y. Chyu, J. R. F. Neto, J. Yano, N. Nathwani, C. Ferreira, P. C. Dimayuga, B. Cercek, S. Kaul, and P. K. Shah Differential Effects of Apolipoprotein A-I-Mimetic Peptide on Evolving and Established Atherosclerosis in Apolipoprotein E-Null Mice Circulation, September 21, 2004; 110(12): 1701 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.G Melo, M Gnecchi, A.S Pachori, K Wang, and V.J Dzau Gene- and cell-based therapies for cardiovascular diseases: current status and future directions Eur. Heart J. Suppl., September 1, 2004; 6(suppl_E): E24 - E35. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Hattori, T. Kujiraoka, T. Egashira, E. Saito, T. Fujioka, S. Takahashi, M. Ito, J. A. Cooper, I. P. Stepanova, M. N. Nanjee, et al. Association of Coronary Heart Disease with Pre-{beta}-HDL Concentrations in Japanese Men Clin. Chem., March 1, 2004; 50(3): 589 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. VanderLaan, C. A. Reardon, and G. S. Getz Site Specificity of Atherosclerosis: Site-Selective Responses to Atherosclerotic Modulators Arterioscler Thromb Vasc Biol, January 1, 2004; 24(1): 12 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fazio and M. F. Linton Apolipoprotein AI as Therapy for Atherosclerosis: Does the Future of Preventive Cardiology Include Weekly Injections of the HDL Protein? Mol. Interv., December 1, 2003; 3(8): 436 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Rader High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis JAMA, November 5, 2003; 290(17): 2322 - 2324. [Full Text] [PDF]
|
|
|
|
|
|
R. E. Moore, M.-a. Kawashiri, K. Kitajima, A. Secreto, J. S. Millar, D. Pratico, and D. J. Rader Apolipoprotein A-I Deficiency Results in Markedly Increased Atherosclerosis in Mice Lacking the LDL Receptor Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1914 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Macdonald, T. L. Terry, L. B. Agellon, P. N. Nation, and G. A. Francis Administration of Tyrosyl Radical-Oxidized HDL Inhibits the Development of Atherosclerosis in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1583 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, I. Zanotti, M. P. Reilly, J. M. Glick, G. H. Rothblat, and D. J. Rader Overexpression of Apolipoprotein A-I Promotes Reverse Transport of Cholesterol From Macrophages to Feces In Vivo Circulation, August 12, 2003; 108(6): 661 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Thiemermann, N. S.A. Patel, E. O. Kvale, G. W. Cockerill, P. A.J. Brown, K. N. Stewart, S. Cuzzocrea, D. Britti, H. Mota-Filipe, and P. K. Chatterjee High Density Lipoprotein (HDL) Reduces Renal Ischemia/Reperfusion Injury J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1833 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Belalcazar, A. Merched, B. Carr, K. Oka, K.-H. Chen, L. Pastore, A. Beaudet, and L. Chan Long-Term Stable Expression of Human Apolipoprotein A-I Mediated by Helper-Dependent Adenovirus Gene Transfer Inhibits Atherosclerosis Progression and Remodels Atherosclerotic Plaques in a Mouse Model of Familial Hypercholesterolemia Circulation, June 3, 2003; 107(21): 2726 - 2732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, R. L. Fitzgerald, J. E. Saffitz, C. F. Semenkovich, and G. Schonfeld Amino Terminal 38.9% of Apolipoprotein B-100 Is Sufficient to Support Cholesterol-Rich Lipoprotein Production and Atherosclerosis Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 668 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Webb, M. A. Bostrom, S. J. Szilvassy, D. R. van der Westhuyzen, A. Daugherty, and F. C. de Beer Macrophage-Expressed Group IIA Secretory Phospholipase A2 Increases Atherosclerotic Lesion Formation in LDL Receptor-Deficient Mice Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 263 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]
|
|
|
|
|
|
H. Duez, Y.-S. Chao, M. Hernandez, G. Torpier, P. Poulain, S. Mundt, Z. Mallat, E. Teissier, C. A. Burton, A. Tedgui, et al. Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor alpha Agonist Fenofibrate in Mice J. Biol. Chem., December 6, 2002; 277(50): 48051 - 48057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Forrester Prevention of Plaque Rupture: A New Paradigm of Therapy Ann Intern Med, November 19, 2002; 137(10): 823 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Brown, M. C. Cheung, A. C. Lee, X.-Q. Zhao, and A. Chait Antioxidant Vitamins and Lipid Therapy: End of a Long Romance? Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1535 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Tangirala, E. D. Bischoff, S. B. Joseph, B. L. Wagner, R. Walczak, B. A. Laffitte, C. L. Daige, D. Thomas, R. A. Heyman, D. J. Mangelsdorf, et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis PNAS, September 3, 2002; 99(18): 11896 - 11901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Choudhury, V. Fuster, J. J. Badimon, E. A. Fisher, and Z. A. Fayad MRI and Characterization of Atherosclerotic Plaque: Emerging Applications and Molecular Imaging Arterioscler Thromb Vasc Biol, July 1, 2002; 22(7): 1065 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. L. King, S. J. Szilvassy, and A. Daugherty Interleukin-4 Deficiency Decreases Atherosclerotic Lesion Formation in a Site-Specific Manner in Female LDL Receptor-/- Mice Arterioscler Thromb Vasc Biol, March 1, 2002; 22(3): 456 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. X. Rong, J. Li, E. D. Reis, R. P. Choudhury, H. M. Dansky, V. I. Elmalem, J. T. Fallon, J. L. Breslow, and E. A. Fisher Elevating High-Density Lipoprotein Cholesterol in Apolipoprotein E-Deficient Mice Remodels Advanced Atherosclerotic Lesions by Decreasing Macrophage and Increasing Smooth Muscle Cell Content Circulation, November 13, 2001; 104(20): 2447 - 2452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah, S. Kaul, J. Nilsson, and B. Cercek Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II Circulation, November 13, 2001; 104(20): 2498 - 2502. [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah, S. Kaul, J. Nilsson, and B. Cercek Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I Circulation, November 6, 2001; 104(19): 2376 - 2383. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Smith An A+ for Macrophages in Reducing Atherosclerosis? Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1710 - 1711. [Full Text] [PDF]
|
|
|
|
|
|
M.-a. Kawashiri, Y. Zhang, D. Usher, M. Reilly, E. Puré, and D. J. Rader Effects of coexpression of the LDL receptor and apoE on cholesterol metabolism and atherosclerosis in LDL receptor-deficient mice J. Lipid Res., June 1, 2001; 42(6): 943 - 950. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Hyka, J.-M. Dayer, C. Modoux, T. Kohno, C. K. Edwards III, P. Roux-Lombard, and D. Burger Apolipoprotein A-I inhibits the production of interleukin-1{beta} and tumor necrosis factor-{alpha} by blocking contact-mediated activation of monocytes by T lymphocytes Blood, April 15, 2001; 97(8): 2381 - 2389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Stein and O. Stein Does Therapeutic Intervention Achieve Slowing of Progression or Bona Fide Regression of Atherosclerotic Lesions? Arterioscler Thromb Vasc Biol, February 1, 2001; 21(2): 183 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. von Eckardstein, J.-R. Nofer, and G. Assmann High Density Lipoproteins and Arteriosclerosis : Role of Cholesterol Efflux and Reverse Cholesterol Transport Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 13 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Shi, X. Wang, N. J. Wang, W. H. McBride, and A. J. Lusis Effect of Macrophage-Derived Apolipoprotein E on Established Atherosclerosis in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, October 1, 2000; 20(10): 2261 - 2266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Dansky and E. A. Fisher High-Density Lipoprotein and Plaque Regression : The Good Cholesterol Gets Even Better Circulation, October 26, 1999; 100(17): 1762 - 1763. [Full Text] [PDF]
|
|
|
|
|
|
R. K. Tangirala, D. Pratico, G. A. FitzGerald, S. Chun, K. Tsukamoto, C. Maugeais, D. C. Usher, E. Pure, and D. J. Rader Reduction of Isoprostanes and Regression of Advanced Atherosclerosis by Apolipoprotein E J. Biol. Chem., January 5, 2001; 276(1): 261 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ishiguro, H. Yoshida, A. S. Major, T. Zhu, V. R. Babaev, M. F. Linton, and S. Fazio Retrovirus-mediated Expression of Apolipoprotein A-I in the Macrophage Protects against Atherosclerosis in Vivo J. Biol. Chem., September 21, 2001; 276(39): 36742 - 36748. [Abstract] [Full Text] [PDF]
|
|